Camostat
Total Payments
$112,800
Transactions
10
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $112,800 | 10 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $112,800 | 10 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| CAMELOT Trial (Camostat Efficacy vs. Placebo for Outpatient Treatment of COVID19) | Sagent Pharmaceuticals, Inc. | $76,800 | 0 |
| Novel Agents for Treatment of High-risk COVID-19 Positive Patients | Sagent Pharmaceuticals, Inc. | $36,000 | 0 |
Top Doctors Receiving Payments for Camostat
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Lexington, KY | $112,800 | 10 |
Ad
Manufacturing Companies
- Sagent Pharmaceuticals, Inc. $112,800
Product Information
- Type Drug
- Total Payments $112,800
- Total Doctors 0
- Transactions 10
About Camostat
Camostat is a drug associated with $112,800 in payments to 0 healthcare providers, recorded across 10 transactions in the CMS Open Payments database. The primary manufacturer is Sagent Pharmaceuticals, Inc..
Payment data is available from 2020 to 2020. In 2020, $112,800 was paid across 10 transactions to 0 doctors.
The most common payment nature for Camostat is "Unspecified" ($112,800, 100.0% of total).
Camostat is associated with 2 research studies, including "CAMELOT Trial (Camostat Efficacy vs. Placebo for Outpatient Treatment of COVID19)" ($76,800).